Loss-of-function mutations in BRCA1/2 lead to a deficiency in the DNA damage repairing pathway called homologous recombination, which could render cancer cells exquisitely vulnerable to the PARP inhibitor (olaparib, OLA). Here, BRCA1 is linked to cancer.